1. Novel potassium N-[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxylhex-1-yl]-L-amino acid dichloroplatinates(II) with high anti-tumor activity and low side reaction
Yuji Wang, Guifeng Kang, Jiawang Liu, Ming Zhao,* Shiqi Peng*. Metallomics, 2012, 4, 441–447
To evaluate the anti-tumor activities of 5a–c, in vitro anti-proliferation assays were performed on HeLa, HL-60, and S180 cell lines, in accordance with the standard MTT method, and cisplatin and oxaliplatin were used as positive controls. The in vitro anti-proliferation activities of 5a–c,cisplatin and oxaliplatin were evaluated at a series of concentrations ranging from 0.004 mM to 400 mM. The IC50 values of cisplatin, oxaliplatin and 5a–c inhibiting the HeLa, HL-60, and S180 cell lines are shown in Fig.2.
2. Exploiting developments in nanotechnology for the preferential delivery of platinum-based anti-cancer agents to tumours: targeting some of the hallmarks of cancer
James P. Parker, Ziga Ude and Celine J. Marmion*. Metallomics, 2016, 8, 43—60
Oxaliplatin is currently used to treat certain (wild-type KRAS) metastatic colorectal cancers expressing epidermal growth factor receptor (EGFR) in combination with the monoclonal antibody Cetuximab. Garrido et al. successfully linked Cetuximab to oxaliplatin-loaded EGFR-targeted liposomes in a pioneering study. This facilitated the selective delivery of both drug entities in a single therapeutic approach. The liposomes demonstrated enhanced tumour drug accumulation as compared to free oxaliplatin or a non-targeted liposome as well as having improved eﬃcacy in mice inoculated with a colorectal cancer cell line which over expresses this receptor.
3. Oxaliplatin vs. cisplatin: competition experiments on their binding to lysozyme
Daniela Marasco, Luigi Messori, Tiziano Marzoc and Antonello Merlino*. Dalton Trans.,2015, 44,10392–10398
These arguments prompted us to investigate the formation of the adducts that are obtained when oxaliplatin and cisplatin are incubated with HEWL. These results are of potential interest if one considers that cisplatin and oxaliplatin might be clinically used in combination and that studies of the cisplatin/oxaliplatin combination on patients with advanced ovarian cancer already revealed acceptable hematologic toxicity, and reversible cumulative neurosensory toxicity. Simultaneous injection of cisplatin and oxaliplatin was reported to produce a synergistic antitumor activity against cisplatin-resistant murine leukemia L1210.